Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 23433400)

1.

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.

Zitron IM, Thakur A, Norkina O, Barger GR, Lum LG, Mittal S.

BMC Cancer. 2013 Feb 22;13:83. doi: 10.1186/1471-2407-13-83.

2.

Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.

Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG.

Clin Cancer Res. 2006 Jan 15;12(2):569-76.

3.

Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.

Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG.

Clin Cancer Res. 2006 Jan 1;12(1):183-90.

4.
6.

Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.

Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1198-205. doi: 10.1002/pbc.24237. Epub 2012 Jun 15.

7.

HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.

Ma J, Han H, Liu D, Li W, Feng H, Xue X, Wu X, Niu G, Zhang G, Zhao Y, Liu C, Tao H, Gao B.

PLoS One. 2013 Aug 27;8(8):e73261. doi: 10.1371/journal.pone.0073261. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/611f44b7-e349-4e7f-9dfe-bdfc724c2f4c.

9.

Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.

Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG.

J Hematother Stem Cell Res. 2001 Apr;10(2):247-60.

PMID:
11359672
10.
11.

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.

Yano H, Thakur A, Tomaszewski EN, Choi M, Deol A, Lum LG.

J Transl Med. 2014 Jul 9;12:191. doi: 10.1186/1479-5876-12-191.

12.
13.

Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Lum LG, Ramesh M, Thakur A, Mitra S, Deol A, Uberti JP, Pellett PE.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1012-22. doi: 10.1016/j.bbmt.2012.01.022. Epub 2012 Feb 5.

14.

Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.

Han H, Ma J, Zhang K, Li W, Liu C, Zhang Y, Zhang G, Ma P, Wang L, Zhang G, Tao H, Gao B.

Int J Oncol. 2014 Dec;45(6):2446-54. doi: 10.3892/ijo.2014.2663. Epub 2014 Sep 18.

PMID:
25242665
15.

An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.

Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH.

Expert Rev Clin Pharmacol. 2013 Jul;6(4):375-86. doi: 10.1586/17512433.2013.811806. Review.

16.
17.

Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.

Pfosser A, Brandl M, Salih H, Grosse-Hovest L, Jung G.

Int J Cancer. 1999 Feb 9;80(4):612-6.

PMID:
9935165
18.

Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.

Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.

Anticancer Res. 2000 May-Jun;20(3A):1551-5.

PMID:
10928069
19.

Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium.

Lum LG, Fok H, Sievers R, Abedi M, Quesenberry PJ, Lee RJ.

Blood Cells Mol Dis. 2004 Jan-Feb;32(1):82-7.

PMID:
14757418
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk